PTC Therapeutics Stock News

PTCT is a commercial stage small cap surviving on a timely loan. Their revenue stream is overdependent on one franchise.

PTC Therapeutics (PTCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near

While the concept of Nasdaq stocks to sell won't resonate too kindly with generally optimistic Americans, it's become a reality. It's not just about the fact that on a year-to-date basis, the benchmar

Mid-cap companies lie in between the slower growth large-cap stocks and the faster-growth small-cap businesses.

The registration-directed phenylketonuria study results are anticipated by the end of the quarter. Management claims there are about 58,000 PKU patients globally that they can target by 2030.

PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings es

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q3 2022 Results Conference Call October 27, 2022 4:30 PM ET Company Participants Kylie O'Keefe - SVP, Head of Global Commercial and Corporate Strategy Stuart Pelt

Shares of PTC Therapeutics Inc. PTCT, -10.87% were down 10.1% in trading on Wednesday morning, the day after the company said enrollment in a Phase 2 clinical trial for its Huntington's disease treatm

PTC Therapeutics (NASDAQ:PTCT ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Kylie O'Keefe - Senior Vice President, Head of Global Commercial & Corporate Strategy St

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -27.54% and 13.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Start Time: 16:30 January 1, 0000 5:36 PM ET PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q1 2022 Earnings Conference Call May 03, 2022, 16:30 PM ET Company Participants Stuart Peltz - Founder and CEO Matthe

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -14.84% and 2.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics has been cooperating with Roche since 2011.

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow